New York State Common Retirement Fund Has $17.64 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

New York State Common Retirement Fund lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 111.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,132 shares of the medical equipment provider’s stock after purchasing an additional 103,931 shares during the quarter. New York State Common Retirement Fund owned 0.28% of Lantheus worth $17,635,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after purchasing an additional 32,551 shares in the last quarter. Moloney Securities Asset Management LLC acquired a new position in Lantheus during the third quarter worth $1,066,000. Massachusetts Financial Services Co. MA acquired a new position in Lantheus during the third quarter worth $25,955,000. Van ECK Associates Corp raised its stake in Lantheus by 58.6% during the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after acquiring an additional 21,604 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after acquiring an additional 3,772 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on LNTH. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $78.23 on Friday. Lantheus Holdings, Inc. has a twelve month low of $56.44 and a twelve month high of $126.89. The firm has a market cap of $5.44 billion, a PE ratio of 13.02 and a beta of 0.44. The business has a fifty day moving average of $90.31 and a 200-day moving average of $97.05.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.